No Detail Found!

Therapeutic E cacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer

Author(s)
Junmei Zhang Department of Medical Oncology, Xi an International Medical Centre Hospital,Xi an,China
Xuezheng Wang Mailman School of Public Health, Columbia University Irving Medical Centre,New York,United States of America
Hongjuan Du Department of Medical Oncology, Chongqing General Hospital,Chongqing,China
Yan Xue Department of Medical Oncology, Xi an International Medical Centre Hospital,Xi an,China
Abstract
Objective: To evaluate the e cacy and safety of eribulin plus anti-angiogenic medicine in metastatic breast cancer (MBC), and explore the potential biomarkers. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Xi an International Medical Centre Hospital, Xi an, China, from May 2022 to 2023. Methodology: A total of 40 MBC patients treated with eribulin were enrolled. Patients were divided into two groups based on whether they received eribulin monotherapy or combined therapy. Median progression-free survival(mPFS), the time from the start of erbium treatment to the time of disease progression, was calculated using the Kaplan-Meier method. Results: The eribulin plus anti-angiogenic medicine treatment group had a significantly prolonged mPFS compared to the group without anti-angiogenic medicine treatment (7.0 months vs. 2.0 months, p <0.001). The multivariate analysis identi ed that the combination of anti-angiogenic therapy (HR = 0.043, p = 0.004) and the occurrence of grade 3-4 neutropenia after the treatment were two predictive factors for longer PFS (HR = 0.322, p = 0.009). In contrast, prior resistance to taxane was predictive of shorter PFS (HR = 4.583, p = 0.019). Other clinic-pathological factors were not significantly associated with PFS. Fisher's exact test showed no significant increase in treatment-related adverse events (all grades) after combination with anti-angiogenic medicine. Conclusion: The eribulin plus anti-angiogenic combination may act as a potential therapy for late-line MBC patients with clinically beneficial therapeutic effects.
Publication Details
Page(s) 682-687
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 6, Year: 2024

Request the full text from PASTIC

Keywords
Eribulin, Anti-angiogenic therapy, Predictive indicators of e cacy, Metastatic Breast Cancer
0

Citations

0

Downloads

68

Views